- Home
- LSTA vs CVKD Comparison
LSTA vs CVKD Comparison
Compare LSTA & CVKD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | LSTA | CVKD |
|---|---|---|
| Founded | 1980 | 2022 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Misc Health and Biotechnology Services | Medicinal Chemicals and Botanical Products |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 20.9M | 20.7M |
| IPO Year | N/A | 2023 |
Fundamental Metrics
Financial Performance| Metric | LSTA | CVKD |
|---|---|---|
| Price | $2.02 | $7.42 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 1 |
| Target Price | $23.50 | ★ $32.00 |
| AVG Volume (30 Days) | 23.4K | ★ 69.7K |
| Earning Date | 11-06-2025 | 11-10-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,070,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.81 | $7.43 |
| 52 Week High | $4.20 | $22.90 |
Technical Indicators
Market Signals| Indicator | LSTA | CVKD |
|---|---|---|
| Relative Strength Index (RSI) | 45.08 | 34.83 |
| Support Level | $1.97 | $7.43 |
| Resistance Level | $2.15 | $12.50 |
| Average True Range (ATR) | 0.12 | 1.10 |
| MACD | 0.02 | -0.15 |
| Stochastic Oscillator | 51.87 | 4.82 |
Price Performance
Historical ComparisonAbout LSTA Lisata Therapeutics Inc.
Lisata Therapeutics Inc is a clinical-stage pharmaceutical company dedicated to the discovery, development, and commercialization of therapies for the treatment of solid tumors and other diseases. Its investigational product, certepetide, is designed to activate a novel uptake pathway that allows co-administered or tethered (i.e., molecularly bound) anti-cancer drugs to target and penetrate solid tumors more effectively. The group has one operating segment, the research and development of its investigational drug product.
About CVKD Cadrenal Therapeutics Inc.
Cadrenal Therapeutics Inc is developing tecarfarin, its drug candidate, for unmet needs in anticoagulation therapy. Tecarfarin is a late-stage novel oral and reversible anticoagulant (blood thinner) designed to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation.